Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rivoceranib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 811803-05-1, Rivoceranib, Apatinib free base, Yn968d1, N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
    Molecular Formula
    C24H23N5O
    Molecular Weight
    397.5  g/mol
    InChI Key
    WPEWQEMJFLWMLV-UHFFFAOYSA-N
    FDA UNII
    5S371K6132
    Rivoceranib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
    2.1.2 InChI
    InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
    2.1.3 InChI Key
    WPEWQEMJFLWMLV-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
    2.2 Other Identifiers
    2.2.1 UNII
    5S371K6132
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Apatinib Mesylate

    2. Rivoceranib

    3. Rivoceranib Mesylate

    4. Yn-968d1

    5. Yn968d1

    2.3.2 Depositor-Supplied Synonyms

    1. 811803-05-1

    2. Rivoceranib

    3. Apatinib Free Base

    4. Yn968d1

    5. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide

    6. N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide

    7. 5s371k6132

    8. N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide

    9. 3-pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-

    10. Unii-5s371k6132

    11. Apatinib (in China)

    12. Rivoceranib [inn]

    13. Rivoceranib (usan/inn)

    14. Rivoceranib [usan]

    15. Rivoceranib [who-dd]

    16. Gtpl7648

    17. Schembl1814966

    18. Chembl3186534

    19. Apatinib Free Base; Yn-968d1

    20. Dtxsid601024366

    21. Amy21302

    22. Bcp02840

    23. Ex-a1794

    24. Hy-13342a

    25. Mfcd21648511

    26. Nsc772886

    27. Nsc799333

    28. S5248

    29. Zinc70466461

    30. Akos024464453

    31. Ccg-268625

    32. Db14765

    33. Ds-7455

    34. Nsc-772886

    35. Nsc-799333

    36. Sb16590

    37. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide

    38. Ncgc00249393-01

    39. Ncgc00249393-08

    40. Ac-27461

    41. Ba175030

    42. Da-35324

    43. Cs-0003200

    44. C76598

    45. D11288

    46. Ab01274807-01

    47. Ab01274807_02

    48. Q27262801

    49. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide

    50. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 397.5 g/mol
    Molecular Formula C24H23N5O
    XLogP34.1
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count6
    Exact Mass397.19026037 g/mol
    Monoisotopic Mass397.19026037 g/mol
    Topological Polar Surface Area90.7 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity608
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)